2022
NYX-2925, a novel N-methyl-D-aspartate Receptor Positive Allosteric Modulator, Showed Antinociceptive Activity in Functional Neuroimaging Evaluations Correlated with Improved Patient-Reported Pain and Fibromyalgia Symptoms
Recent in vivo advances of spirocyclic scaffolds for drug discovery
2021
NYX-2925, a novel, non-opioid, small-molecule modulator of the N-Methyl-D-Aspartate Receptor (NMDAR), demonstrates potential to treat chronic, supraspinal centralized pain conditions
2019
NYX-2925 impacts functional and chemical neuroimaging biomarkers and patient-reported outcomes of pain in patients with fibromyalgia
NYX-2925, a novel NMDA receptor modulator, improves chronic pain and its affective state in rats with paclitaxel-induced neuropathy
The novel NMDA receptor modulator, NYX-2925, enhances NMDAR-mediated current and LTP, induces changes in cell intrinsic properties, and alters firing properties in layer 5 pyramidal neurons of rat mPFC
NYX-2925, a novel NMDA receptor modulator, improves chronic pain and its affective state in rats with paclitaxel-induced neuropathy
NYX-2925 induces metabotropic NMDAR signaling that enhances synaptic NMDAR and AMPAR
NMDAR activation regulates the daily rhythms of sleep and mood
A translational EEG-based approach to assess modulation of long-lasting NMDAR-dependent synaptic plasticity
2018
NYX-2925 is a Novel N-Methyl-D-aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain
NYX-2925, A Novel N-methyl-D-aspartate Receptor Modulator: A First-in-Human, Randomized, Double-blind Study of Safety and Pharmacokinetics in Adults
NYX-2925 facilitates auditory-evoked long-term potentiation in rats: a translational approach for measuring NMDA receptor-mediated synaptic plasticity
Enhancement of synaptic plasticity by NYX-2925: Sleep cycle EEG studies in rats
Preclinical Through Early-Stage Clinical Development of a Novel NMDA Receptor Modulator, NYX-2925
NYX-2925 Reverses the Decrease in Hedonic Ultrasonic Vocalization and the Increase in Aversive Vocalization Observed With Cci-Induced Neuropathic Pain in Rats
NYX-2925 Improves Both Pain and Its Affective States in the Rat Chronic Constriction Injury Model of Neuropathic Pain
NYX-2925 re-normalizes synaptic-plasticity associated protein expression in rat mPFC: a potential mechanism for the compound’s analgesic effect in neuropathic pain
NYX-2925, a novel NMDA receptor modulator, renormalizes synaptic plasticity associated cortical protein expressions in rats with CCI: a potential mechanism for the compound’s analgesic effect in neuropathic pain
The NMDA Receptor Modulator NYX-2925 Shows Therapeutic Potential in Preclinical Models for the Treatment of Neuropathic Pain
NYX-2925 facilitates auditory-evoked long-term potentiation in rats: a translational approach for measuring NMDA receptor-mediated synaptic plasticity
The novel NMDA receptor modulator NYX-2925 enhances dendritic spine autonomous structural and functional plasticity in vitro
2017
NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory
NYX-2925, a Novel NMDA Receptor Modulator, Shows Efficacy in Neuropathic Pain that is NMDA and AMPA Receptor Dependent and Appears to Be Driven through Brain, but NOT Spinal Circuitry
The NMDA Receptor Modulator NYX-2925 Shows Therapeutic Potential in Preclinical Models for the Treatment of Neuropathic Pain
2016
JY-515,317 (NYX-2925) is a NMDA receptor modulator with glycine site partial agonist-like properties: in vitro and in vivo pharmacology
JY-515,317 (NYX-2925), an NMDA receptor modulator with glycine site partial agonist-like properties, shows therapeutic potential for the treatment of neuropathic pain
JY-515,317 (NYX-2925), a NMDA receptor modulator with glycine site partial agonist-like properties, has neuroprotective effects in a rat model of blast-induced traumatic brain injury
NYX-2925 is a NMDA receptor modulator with glycine site partial agonist-like properties: in vitro and in vivo characterization
NYX-2925, an NMDA receptor modulator with glycine site partial agonist-like properties, induces rapid and long-lasting analgesic effect in multiple rat models of neuropathic pain
